In particular, compound 41, both highly potent and selective against USP7, is orally bioavailable and demonstrates tumor growth inhibition in both p53 wild type and p53 mutant cancer cell lines in xenograft studies61, suggesting that the inhibition of USP7 could suppress tumor growth through multiple pathways, thereby delineating a possible clinical application. Here, USP7 is linked to cancer.